

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4031267

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
HERON THERAPEUTICS, INC.	08/05/2016

RECEIVING PARTY DATA

Name:	TANG CAPITAL PARTNERS, LP
Street Address:	4747 EXECUTIVE DRIVE, SUITE 510
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121

PROPERTY NUMBERS Total: 36

Property Type	Number
Patent Number:	5955109
Patent Number:	5939453
Patent Number:	8252305
Patent Number:	8252306
Patent Number:	6790458
Patent Number:	6861068
Patent Number:	6613355
Patent Number:	8252304
Patent Number:	8715710
Patent Number:	6863782
Patent Number:	6590059
Patent Number:	6822000
Patent Number:	7163694
Patent Number:	7456213
Application Number:	14652070
Application Number:	14210263
Application Number:	14210318
Application Number:	14213658
Application Number:	14264489
Application Number:	62052948

PATENT

Property Type	Number
Application Number:	15083071
Application Number:	14859013
Application Number:	15012532
Application Number:	14946493
Application Number:	62136333
Application Number:	14253615
Application Number:	14691464
Application Number:	62341557
Application Number:	14691491
Application Number:	14765179
Application Number:	15108986
Application Number:	62360875
PCT Number:	US2015051050
PCT Number:	US2016015992
PCT Number:	US2015026695
PCT Number:	US2015026720

CORRESPONDENCE DATA

Fax Number: (949)475-4754

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 949-451-3800

Email: skann@gibsondunn.com

Correspondent Name: STEPHANIE S. KANN, SENIOR PARALEGAL

Address Line 1: 3161 MICHELSON DRIVE

Address Line 2: GIBSON, DUNN & CRUTCHER LLP

Address Line 4: IRVINE, CALIFORNIA 92612

ATTORNEY DOCKET NUMBER:	42441-00009
NAME OF SUBMITTER:	STEPHANIE S. KANN
SIGNATURE:	/stephanie s. kann/
DATE SIGNED:	08/30/2016

Total Attachments: 13

- source=HeronPatent Security Agreement#page1.tif
- source=HeronPatent Security Agreement#page2.tif
- source=HeronPatent Security Agreement#page3.tif
- source=HeronPatent Security Agreement#page4.tif
- source=HeronPatent Security Agreement#page5.tif
- source=HeronPatent Security Agreement#page6.tif
- source=HeronPatent Security Agreement#page7.tif
- source=HeronPatent Security Agreement#page8.tif
- source=HeronPatent Security Agreement#page9.tif

source=HeronPatent Security Agreement#page10.tif
source=HeronPatent Security Agreement#page11.tif
source=HeronPatent Security Agreement#page12.tif
source=HeronPatent Security Agreement#page13.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this "Patent Security Agreement") is made as of August 5, 2016, among HERON THERAPEUTICS, INC., a Delaware corporation ("Grantor"), and TANG CAPITAL PARTNERS, LP, in its capacity as a Holder and Agent.

RECITALS

WHEREAS, Heron has entered into that certain Secured Promissory Note (the "Note") dated as of August 5, 2016 in favor of Agent, as Holder, and

WHEREAS, the Holder is willing to make the financial accommodations to Heron as provided for in the Note, but only upon the condition, among others, that Grantor shall have executed and delivered to Agent, as representative of the Holder for the benefit of the Holder, that certain Security Agreement dated as of August 5, 2016 (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the "Security Agreement");

WHEREAS, pursuant to the Security Agreement, Grantor is required to execute and deliver to Agent this Patent Security Agreement;

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantor hereby agrees as follows:

1. DEFINED TERMS. All capitalized terms used but not otherwise defined herein have the meanings given to them in the Security Agreement.
2. GRANT OF SECURITY INTEREST IN PATENT COLLATERAL. Grantor hereby grants to Agent a continuing security interest in all of Grantor's right, title and interest in, to and under the following, whether presently existing or hereafter created or acquired (collectively, the "Patent Collateral"):
 - (a) all of its Patents and Patent Intellectual Property Licenses to which it is a party including those referred to on Schedule I hereto;
 - (b) all reissues, continuations or extensions of the foregoing; and
 - (c) all products and proceeds of the foregoing, including any claim by Grantor against third parties for past, present or future infringement or dilution of any Patent or any Patent licensed under any Intellectual Property License.
3. SECURITY FOR OBLIGATIONS. This Patent Security Agreement and the Security Interest created hereby secures the payment and performance of all the Secured Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Patent Security Agreement secures the payment of all amounts which constitute part of the Secured Obligations and would be owed by Grantor, or any of them, to Agent,

whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving Grantor.

4. SECURITY AGREEMENT. The security interests granted pursuant to this Patent Security Agreement are granted in conjunction with the security interests granted to Agent pursuant to the Security Agreement. Grantor hereby acknowledges and affirms that the rights and remedies of Agent with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

5. AUTHORIZATION TO SUPPLEMENT. If Grantor shall obtain rights to any new patentable inventions or become entitled to the benefit of any patent application or patent for any reissue, division, or continuation, of any patent, the provisions of this Patent Security Agreement shall automatically apply thereto. Grantor shall give prompt notice in writing to Agent with respect to any such new patent rights. Without limiting Grantor's obligations under this Section 5, Grantor hereby authorizes Agent unilaterally to modify this Agreement by amending Schedule I to include any such new patent rights of Grantor. Notwithstanding the foregoing, no failure to so modify this Patent Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Agent's continuing security interest in all Collateral, whether or not listed on Schedule I.

6. COUNTERPARTS. This Patent Security Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such separate counterparts shall together constitute but one and the same instrument. In proving this Patent Security Agreement or any other Note Document in any judicial proceedings, it shall not be necessary to produce or account for more than one such counterpart signed by the party against whom such enforcement is sought. Any signatures delivered by a party by facsimile transmission or by e-mail transmission shall be deemed an original signature hereto.


7. CONSTRUCTION. Unless the context of this Patent Security Agreement or any other Note Document clearly requires otherwise, references to the plural include the singular, references to the singular include the plural, the terms "includes" and "including" are not limiting, and the term "or" has, except where otherwise indicated, the inclusive meaning represented by the phrase "and/or." The words "hereof," "herein," "hereby," "hereunder," and similar terms in this Patent Security Agreement or any other Note Document refer to this Patent Security Agreement or such other Note Document, as the case may be, as a whole and not to any particular provision of this Patent Security Agreement or such other Note Document, as the case may be. Section, subsection, clause, schedule, and exhibit references herein are to this Patent Security Agreement unless otherwise specified. Any reference in this Patent Security Agreement or in any other Note Document to any agreement, instrument, or document shall include all alterations, amendments, changes, extensions, modifications, renewals, replacements, substitutions, joinders, and supplements, thereto and thereof, as applicable (subject to any restrictions on such alterations, amendments, changes, extensions, modifications, renewals, replacements, substitutions, joinders, and supplements set forth herein). Any reference herein or in any other Note Document to the satisfaction or repayment in full of the Secured Obligations shall mean the repayment in full in cash (or cash collateralization in accordance with the terms hereof) of all Obligations other than unasserted contingent indemnification Secured Obligations.

Any reference herein to any Person shall be construed to include such Person's successors and assigns. Any requirement of a writing contained herein or in any other Note Document shall be satisfied by the transmission of a Record and any Record so transmitted shall constitute a representation and warranty as to the accuracy and completeness of the information contained therein.

[Signature page follows]

IN WITNESS WHEREOF, Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.


HERON THERAPEUTICS, INC., a
Delaware corporation

By: 
Name: David Szekeres
Title: SVP, General Counsel

ACCEPTED AND
ACKNOWLEDGED BY:

TC MANAGEMENT SERVICES,
LLC, as Agent

By: Tang Advisors, LLC,
its manager

By: 
Name: KEVIN TANA
Title: MANAGER

Schedule I

<u>Country</u>	<u>Application No.</u>	<u>Case Status</u>	<u>Application Date</u>	<u>Registration No.</u>	<u>Registration Date</u>	<u>Title</u>
US	08/079220	Registered	6/17/1993	5955109	9/21/1999	METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY OF RETINOIC ACID
US	09/090648	Registered	6/4/1998	5939453	8/17/1999	PEG-POE, PEG-POE-PEG, AND POE-PEG-POE BLOCK COPOLYMERS
US	13/279938	Registered	10/24/2011	8252305	8/28/2012	METHODS OF TREATING EMESIS UTILIZING SEMI-SOLID DELIVERY PHARMACEUTICAL COMPOSITIONS COMPRISING GRANISETRON
US	13/279949	Registered	10/24/2011	8252306	8/28/2012	PROCESS FOR PREPARING A SEMI-SOLID DELIVERY VEHICLE COMPRISING GRANISETRON
US	10/409408	Registered	4/7/2003	6790458	9/14/2004	PHARMACEUTICAL COMPOSITIONS USING SEMI-SOLID DELIVERY VEHICLE
US	10/765768	Registered	1/26/2004	6861058	3/1/2005	PHARMACEUTICAL COMPOSITIONS USING SEMI-SOLID DELIVERY VEHICLE
US	08/854180	Registered	5/11/2001	6613355	9/2/2003	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
France	05802951.3	Registered	4/16/2007	1796629	11/12/2014	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
US	12/664881	Registered	9/22/2009	8252304	8/28/2012	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF GRANISETRON
US	13/552083	Registered	7/18/2012	8715710	5/6/2014	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF GRANISETRON

Taiwan	094133844	Registered	9/28/2005	1407166	9/11/2013	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
United Kingdom	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Austria	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Denmark	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Finland	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Germany	01935418.2	Registered	10/16/2002	80115631.5	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Luxembourg	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
US	10/298188	Registered	11/15/2002	6883782	3/6/2005	METHOD OF PREPARING DI(KETENE ACETALS)
US	09/854436	Registered	5/11/2001	6590059	7/8/2003	BIOERODIBLE POLY(ORTHOESTERS FROM DIOXOLANE-BASED DIKETENE ACETALS)
US	10/330781	Registered	12/24/2002	6822000	11/23/2004	BIOERODIBLE POLY(ORTHOESTERS) FROM DIOXOLANE-BASED DIKETENE ACETALS
US	11/371959	Registered	3/8/2006	7163694	1/16/2007	BIOERODIBLE POLY(ORTHOESTERS) FROM DIOXANE-BASED DI(KETENE ACETALS), AND BLOCK COPOLYMERS CONTAINING THEM
US	11/392989	Registered	3/28/2006	7456213	11/25/2008	PEG-POLY(ORTHOESTER) GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS

Canada	2242631	Registered	7/3/1998	2242631	9/9/2008	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
EP	97901352.1	EP Granted	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Japan	525320/1997	Registered	7/3/1998	4015194	11/28/2007	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Brazil	PI9706980-4	Registered	7/3/1998	PI9706980-4	3/1/2008	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Finland	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
France	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Denmark	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Germany	97901352.1	Registered	8/3/1998	69703430.5	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Greece	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Sweden	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Spain	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Portugal	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Netherlands	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Monaco	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND

						BIOERODIBILITY
Luxembourg	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Italy	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Ireland	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Switzerland	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
United Kingdom	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Austria	97901352.1	Registered	8/3/1998	E197310	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
Netherlands	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Portugal	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Spain	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Switzerland	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Canada	2445638	Registered	10/27/2003	2445638	2/9/2010	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
EP	01935418.2	EP Granted	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
France	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS

Belgium	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Sweden	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Greece	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Ireland	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Italy	01935418.2	Registered	10/16/2002	1280558	12/7/2005	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Germany	05802951.3	Registered	4/18/2007	602005045170.6	11/12/2014	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Switzerland	05802951.3	Registered	4/18/2007	1796629	11/12/2014	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Sweden	05802951.3	Registered	4/18/2007	1796629	11/12/2014	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Spain	05802951.3	Registered	4/18/2007	1796629	11/12/2014	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Italy	05802951.3	Registered	4/18/2007	502015000005908	11/12/2014	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
EP	05802951.3	EP Granted	4/18/2007	1796629	11/12/2014	SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Belgium	97901352.1	Registered	8/3/1998	0869986	11/2/2000	POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY
US	14/852070	Published	6/12/2015			PHARMACEUTICAL COMPOSITION COMPRISING ANTIEMETIC COMPOUNDS AND POLYORTHOESTER

US	14/210263	Published	3/13/2014		COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT
US	14/210316	Published	3/13/2014		COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT
Taiwan	103109528	Published	3/14/2014		COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT
US	14/213658	Allowed	3/14/2014		COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT
US	14/264489	Published	4/29/2014		COMPOSITIONS AND METHODS FOR INJECTION OF A BIODEGRADABLE POLYMER-BASED DELIVERY SYSTEM
US	62/052948	Pending	9/19/2014		EMULSION FORMULATIONS OF APREPITANT
US	15/083071	Published	3/28/2016		EMULSION FORMULATIONS OF APREPITANT
US	14/859013	Published	9/16/2015		EMULSION FORMULATIONS OF APREPITANT
PCT	PCT/US2015/051050	Published	9/18/2015		EMULSION FORMULATIONS OF APREPITANT
US	15/012532	Pending	2/1/2016		EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST AND USES THEREOF
US	14/946483	Published	11/19/2015		METHODS FOR ENHANCING STABILITY OF POLYORTHOESTERS AND THEIR FORMULATIONS
PCT	PCT/US2016/015992	Pending	2/1/2016		EMULSION COMPRISING AN NK-1 RECEPTOR ANTAGONIST
US	62/136333	Pending	3/20/2015		COMPOSITIONS FOR DELIVERY OF BUPRENORPHINE

Japan	2012-4-376	Published	3/1/2012		SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
EP	14192547.9	Published	11/10/2014		SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Japan	2014-232639	Published	11/17/2014		SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
US	14/253515	Published	4/15/2014		SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
Hong Kong	16101403.1	Pending	9/27/2005		SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS
PCT	PCT/US2015/026695	Published	4/20/2015		LONG-ACTING POLYMERIC DELIVERY SYSTEMS
US	14/691464	Published	4/20/2015		LONG-ACTING POLYMERIC DELIVERY SYSTEMS
Taiwan	104112718	Published	4/21/2015		LONG-ACTING FORMULATIONS FOR TREATMENT OF PAIN
US	62/341557	Pending	5/25/2016		LONG-ACTING POLYMERIC DELIVERY SYSTEMS
US	14/691491	Published	4/20/2015		COMPOSITIONS OF A POLYORTHOESTER AND AN ORGANIC ACID EXCIPIENT
PCT	PCT/US2015/026720	Published	4/20/2015		COMPOSITIONS OF A POLYORTHOESTER AND AN ORGANIC ACID EXCIPIENT
EP	13814394.6	Pending	6/26/2015		PHARMACEUTICAL COMPOSITION COMPRISING ANTIEMETIC COMPOUNDS AND POLYORTHOESTER
US	14/765179	Published	7/31/2015		METHOD OF TREATING PATIENTS NON-RESPONSIVE TO PALONOSETRON
Australia	2014228313	Pending	9/7/2015		COMPOSITIONS OF A POLYORTHOESTER

					ER AND AN APROTIC SOLVENT
Canada	2908866	Pending	9/14/2015		COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT
China	201460028192.5	Published	11/16/2015		COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT
EP	14714137.8	Published	10/14/2015		COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT
Japan	2016-502182	Published	9/10/2015		COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT
Republic of Korea	10-2015-7029636	Pending	10/15/2015		COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT
Mexico	MX/a/2015/012887	Pending	9/14/2016		COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT
US	15/109986	Pending	6/29/2016		POLYMER-BASED COMPOSITIONS FOR EXTENDED RELEASE OF PROTEINS
EP	14877044.9	Pending	6/29/2016		POLYMER-BASED COMPOSITIONS FOR EXTENDED RELEASE OF PROTEINS
US	62/360875	Pending	7/11/2016		POWERED DELIVERY SYSTEM